# A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis

> **NCT00131300** · PHASE3 · COMPLETED · sponsor: **Genzyme, a Sanofi Company**

## Conditions studied

- Osteoarthritis
- Musculoskeletal Diseases

## Interventions

- **DEVICE:** Synvisc (hylan G-F 20)

## Key facts

- **NCT ID:** NCT00131300
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** —
- **Final completion:** 2006-02
- **Target enrollment:** — (—)
- **Last updated:** 2015-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00131300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00131300, "A Study of the Safety and Efficacy of Synvisc in Patients With Symptomatic Shoulder Osteoarthritis". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT00131300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*